Thomas Robert Cech[a] (born 8 December 1947) is an American chemist who shared the 1989Nobel Prize in Chemistry withSidney Altman for their discovery of the catalytic properties ofRNA.
He has also studiedtelomeres, and his lab discovered an enzyme, TERT (telomerase reverse transcriptase), which is part of the process of restoring telomeres after they are shortened during cell division.[4]
In 1975, Cech completed his PhD in chemistry at theUniversity of California, Berkeley and in the same year, he entered theMassachusetts Institute of Technology where he engaged in postdoctoral research.[7] In 1978, he obtained his first faculty position at theUniversity of Colorado where he lectured undergraduate students in chemistry andbiochemistry, and where he remains on the faculty, currently as distinguished professor in the department of biochemistry. In 2000, Cech succeededPurnell Choppin as president of theHoward Hughes Medical Institute inMaryland. He also continued to head his biochemistry laboratory at the University of Colorado, Boulder. On April 1, 2008, Cech announced that he would step down as the president ofHHMI, to return to teaching and research, in spring 2009.[8] Returning to Boulder, Cech became the first executive director of the BioFrontiers Institute, a position he held until 2020. He also taught general chemistry to freshmen.
Cech is the author ofThe Catalyst: RNA and the Quest to Unlock Life’s Deepest Secrets, published in June 2024.[9]
Cech's main research area is that of the process oftranscription in the nucleus of cells. He studies how thegenetic code ofDNA is transcribed intoRNA. In the 1970s, Cech had been studying thesplicing of RNA in the unicellular organismTetrahymena thermophila when he discovered that an unprocessed RNA molecule could splice itself. In 1982, Cech became the first to show that RNA molecules are not restricted to being passive carriers of genetic information – they can havecatalytic functions and can participate in cellular reactions.[10] RNA-processing reactions and protein synthesis onribosomes in particular are catalysed by RNA. RNAenzymes are known asribozymes and have provided a new tool for gene technology. They also have the potential to provide new therapeutic agents – for example, they have the ability to destroy and cleave invading,viral RNAs.
Cech's second area of research is ontelomeres, the structure that protects the ends ofchromosomes. Telomeres are shortened with every duplication of DNA, and must be lengthened again. He studiestelomerase, the enzyme that copies the telomeric sequences and lengthens them.[10] The active site protein subunits of telomerase comprise a new class ofreverse transcriptases, enzymes previously thought to be restricted to viruses andtransposable elements.Telomerase is activated in 90% of human cancers. Therefore, a drug that would inhibit its activity could be useful in treatingcancer.
David Oshinsky, "Vaccines at Warp Speed" (review ofThomas R. Cech,The Catalyst: RNA and the Quest to Unlock Life's Deepest Secrets, Norton, 2024, 292 pp.),The New York Review of Books, vol. LXXII, no. 5 (27 March 2025), pp. 48–50. In order to createCovid-19vaccines "[t]here was no need, as with earlier vaccines, to grow, attenuate, and purify large amounts ofvirus – in this caseSARS-CoV-2 – ... because the vaccine no longer contains it. Instead, syntheticmRNA instructs the cells to create a harmless fragment ofSARS-CoV-2 that will trigger theimmune system to recognize and destroy the virus... [T]he body becomes the factory." (p. 49.) The success of the Covid-19 vaccines "recast the importance of RNA.... [I]t is almost a given, as [the book's author]Cech makes clear, thatRNA will power the next generation ofpharmaceuticals, which will move beyondinfectious diseases to those caused by a 'missing or mutatedprotein,' such asmuscular dystrophy, and numerouscancers caused by 'normal cellular processes gone awry.'... [The question arises, however:] Will this growing focus on 'disease-driven research' overshadow the more traditional 'curiosity-driven' research so vital to scientific advancement?" (p. 50.)